# Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)

> **NCT05134974** · PHASE3 · COMPLETED · sponsor: **Ocuphire Pharma, Inc.** · enrollment: 368 (actual)

## Conditions studied

- Mydriasis
- Dilation

## Interventions

- **DRUG:** Phentolamine Ophthalmic Solution 0.75%
- **DRUG:** Phentolamine Ophthalmic Solution Vehicle

## Key facts

- **NCT ID:** NCT05134974
- **Lead sponsor:** Ocuphire Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-18
- **Primary completion:** 2022-03-18
- **Final completion:** 2022-03-29
- **Target enrollment:** 368 (ACTUAL)
- **Last updated:** 2023-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05134974

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05134974, "Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (MIRA-3)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05134974. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*